Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by georgesoreloseon Jun 13, 2017 5:11pm
162 Views
Post# 26358536

"Personalized Medicine" key words from today's NR...

"Personalized Medicine" key words from today's NR...I believe "PM" will be a driving force in medicine over the next decade.

Tomorrow, another holding of mine ( I own less than my TLT position ) T.EDT will "spill their data load" in Italy at a major conference.  Their drive to FDA phase III success is totally dependent upon "PERSONALIZED MEDICINE"...here are key words from our release today

The clinical data for the initial three patients treated in the Study with the recommended starting dose of TLD-1433 PDC (0.35 mg/cm2), which laid the groundwork for an advanced , personalized and patient specific PDT platform technology was presented at the 16th IPA World Congress.
Read more at https://www.stockhouse.com/news/press-releases/2017/06/13/theralase-presents-dosimetry-planning-at-international-world-congress#fko1PukF2KiQedvB.99
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities